Ionis Pharmaceuticals, Inc. reported earnings results for the third quarter and nine months ended September 30, 2022. For the third quarter, the company reported revenue was USD 160 million compared to USD 133 million a year ago. Net loss was USD 47 million compared to USD 82 million a year ago. Basic loss per share from continuing operations was USD 0.33 compared to USD 0.58 a year ago.
For the nine months, revenue was USD 435 million compared to USD 370 million a year ago. Net loss was USD 217 million compared to USD 253 million a year ago. Basic loss per share from continuing operations was USD 1.53 compared to USD 1.8 a year ago.